Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

re results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

The Company is still in the development stage and has not generated any revenues. From inception through March 31, 2007, it incurred net losses and negative cash flows from operating activities of approximately $22.7 million and $17.4 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.

In order to obtain the regulatory approvals necessary to commercialize its current or future product candidates, from time to time the Company will need to raise funds through public or private equity offerings, debt financings or additional corporate collaboration and licensing arrangements. Availability of financing depends upon a number of factors beyond the Company's control, including market conditions and interest rates. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders. Management believes that the Company's current resources will enable it to continue as a going concern through at least March 31, 2008.

The Company will need to conduct future clinical trials for treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.

There is no assurance as to when, or if, th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... 25 BiPar Sciences, Inc., a,privately held ... molecular biomarker data demonstrating the overexpression,of the ... ovarian, breast and lung tumors. The research ... specific types of cancer. This,insight is being ...
... ... inhibitors, SAN FRANCISCO, ... the discovery, rapid,development and commercialization of therapies for solid tumors and,hematological ... the 2007 AACR-NCI-EORTC International Conference that,describe how its proprietary CLIMB technology ...
Cached Medicine Technology:BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 3
(Date:7/11/2014)... Datalogic brings a new and innovative scanner ... With their new Gryphon GD4400 and GM4400 ... devastating MRSA, which claimed 5,500 lives, becomes more preventable. ... and the Gryphon GM4400-HC 2D readers can scan nearly ... barcodes off of troublesome LCD monitors, smartphones, and other ...
(Date:7/11/2014)... Boston, MA (PRWEB) July 11, 2014 ... save at least $50 billion in fuel ... effect immediately. The current GHG standards ... manufacturers have taken it upon themselves to ... they include: , 1.    Idle reduction technologies , ...
(Date:7/11/2014)... (HealthDay News) -- Children who have emergency surgery ... and potentially even death than those who have ... However, the Johns Hopkins researchers noted that the ... analyzed data on nearly 440,000 simple emergency surgeries ... a 22-year period. The surgeries are considered ...
(Date:7/11/2014)... Oakland, CA (PRWEB) July 11, 2014 Ticket ... tickets at the Concord Pavilion . When it comes to ... from Luke Bryan. The 37-year-old Georgia native is one of the ... in the entertainment business. Bryan is currently out on his “That’s ... Among the many stops the tour will be making through the ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, ... exclusively to cell and gene therapies for cancer ... the organization as Senior Development Officer. , Corday ... securing gifts and addressing influential donors. Prior to ... for NewYork Presbyterian Hospital/Columbia University Medical Center, where ...
Breaking Medicine News(10 mins):Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... Bush,today visited the Maamobi Polyclinic in the Greater ... being implemented by AED to control,malaria., Through ... commercial,sector to increase the availability and affordability of ... and five,other sub-Saharan African countries, and is supported ...
... the recently,released Audit Bureau of Circulations FAS-FAX report, ... paid circulation in the,period from July 2007 through ... year. This increase was substantially larger than that ... Self, Shape, Health, Martha,Stewart Living and Natural Health., ...
... Provides Financial Guidance for 2008, BIRMINGHAM, Ala., Feb. 20 ... for its fourth quarter and,full year ended December 31, 2007., ... 14.7% decrease from,fourth quarter 2006 revenue of $33.5 million. The ... share. In the fourth quarter of 2006, the,Company earned net ...
... Patients with rheumatoid arthritis are twice as likely ... a doctor about it, according to researchers at the ... Rheumatoid arthritis (RA) the most common form of ... by inflammation of joint tissues, persistent pain, functional disability, ...
... Mouse study suggests it could help control diabetes in humans ... found a way to convert human embryonic stem (ES) cells ... ease a diabetes-like condition in mice, a new study says. ... lead to a renewable source of cells for treatment of ...
... in breast arteries upped chances of cardiovascular trouble, ... In addition to detecting breast cancer in its early ... predict which women are at risk for strokes. , ... -- what doctors call benign arterial calcifications -- were ...
Cached Medicine News:Health News:First Lady Laura Bush Visits AED/Netmark Malaria-Control Project in Ghana 2Health News:Yoga Journal Circulation Increases 5.8 Percent in Second Half of 2007 from Same Period Previous Year 2Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 2Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 3Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 4Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 5Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 6Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 7Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 8Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 9Health News:Doctors should watch for depression in arthritis patients 2Health News:Researchers Make Stem Cells That Secrete Insulin 2Health News:Mammograms Might Spot Stroke Risk 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: